Maximum Reduction. The maximum aggregate reduction with respect to the royalty rate for a Product in any calendar quarter during the applicable Royalty Term in any country pursuant to Sections 3.1.5 (Royalty Reduction), 3.1.6 (Biosimilar Competition) and 3.1.7 (Third-Party Intellectual Property) shall be [***].
Appears in 3 contracts
Samples: Quality Agreement (Akero Therapeutics, Inc.), Quality Agreement (Akero Therapeutics, Inc.), Quality Agreement (Akero Therapeutics, Inc.)
Maximum Reduction. The maximum aggregate reduction with respect to the royalty rate for a any Product in any calendar quarter during the applicable Royalty Term in any country pursuant to Sections 3.1.5 8.2.5 (Royalty Reduction), 3.1.6 (Biosimilar Competition) and 3.1.7 8.2.6 (Third-Party Intellectual Property) shall be […***…] percent ([…***…]%).
Appears in 2 contracts
Samples: Research Collaboration and License Agreement (Kite Pharma, Inc.), Research Collaboration and License Agreement (Kite Pharma, Inc.)
